We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01580241
First Posted: April 18, 2012
Last Update Posted: August 22, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
University of Oklahoma
April 17, 2012
April 18, 2012
August 22, 2017
October 2010
July 2015   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01580241 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer
Expression Patterns of Stem Cell Marker Doublecortin and CaM Kinase-Like-1 (DCAMKL-1) in Human Pancreatic Adenocarcinoma
The investigators believe DCAMKL-1 is a stem cell tumor marker and is elevated in patients with pancreatic cancer. The investigators would like to analyze its expression pre and post treatment, to gauge the correlation between current pancreatic cancer therapies and the expression of DCAMKL-1
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Human patients with pancreatic cancer undergo various treatments for pancreatic cancer. We will examine the expression of Dcamkl-1 pre and post therapy (including, chemotherapy only, surgery only, neoadjuvant and adjuvant therapies) to correlate treatment with a change in DCAMKl-1 expression.
Pancreatic Cancer
Not Provided
  • Surgery group
    Patients with pancreatic cancer who undergo surgical treatment only
  • Chemotherapy group
    Patients with pancreatic cancer who undergo chemotherapy treatment only
  • Neoadjuvant group
    Patients with pancreatic cancer who undergo neoadjuvant chemotherapy and surgery
  • Adjuvant group
    Patients with pancreatic cancer who undergo surgery followed by chemotherapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
60
December 2018
July 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • pancreatic cancer

Exclusion Criteria:

  • age < 18, history of other types of cancer
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01580241
2606
No
Not Provided
Not Provided
University of Oklahoma
University of Oklahoma
Not Provided
Principal Investigator: Courtney Houchen, MD University of Oklahoma
University of Oklahoma
August 2017